The patent expiry of semaglutide in India has opened avenues for greater accessibility to obesity and diabetes treatment. However, it also raises concerns regarding misuse and regulatory challenges. Examine the implications of its generic entry on public health, pharmaceutical markets, and ethical usage.

Question

PocketIAS · Accepted Answer

INTRODUCTION

Semaglutide, a GLP-1 receptor agonist used for diabetes and obesity management, is witnessing patent expiry in India, enabling generic production.
While this improves access and affordability, it raises concerns about misuse and regulatory oversight.

IMPLICATIONS FOR PUBLIC HEALTH

Improved Accessibility: Lower prices can expand treatment to a larger population with diabetes and obesity.
Preventive Potential: Effective weight management may reduce NCD burden (CVDs, hypertension).
Risk of Misuse: Use for cosmetic weight loss without medical supervision.
Adverse Effects: Unregulated consumption may lead to side effects and long-term health risks.

IMPACT ON PHARMACEUTICAL MARKETS

Increased Competition: Entry of generics reduces monopoly pricing and expands market players.
Price Rationalisation: Significant cost reduction improves affordability.
Innovation Concerns: Reduced incentives for R&D by originator companies.
Supply Chain Expansion: Greater domestic manufacturing capacity.

REGULATORY AND ETHICAL CHALLENGES

Off-label Use: Promotion for non-medical weight loss raises ethical concerns.
Quality Control Issues: Ensuring bioequivalence and safety of generics.
Prescription Regulation: Risk of over-the-counter or online misuse.
Inequitable Access: Urban bias may persist despite lower prices.

MEASURES FOR RESPONSIBLE AND ETHICAL USAGE

Strengthening Regulation: Strict enforcement by CDSCO on approval and marketing practices.
Prescription-based Access: Ensure rational use through medical supervision.
Clinical Guidelines: Clear protocols for obesity and diabetes treatment.
Awareness Campaigns: Educate public on risks of misuse.
Pharmacovigilance Systems: Monitor adverse drug reactions.
Equitable Distribution: Inclusion in public health programmes where appropriate.

CONCLUSION

The generic entry of semaglutide offers a transformative opportunity for NCD management, but requires robust regulation and ethical safeguards to ensure safe, equitable, and rational use.

✍️ Practice Mode

Write. Evaluate. Improve. Repeat.

The model answer is ready.

Comments (0)